about
CFD simulations of enhanced condensational growth (ECG) applied to respiratory drug delivery with comparisons to in vitro dataCharacterization of respiratory drug delivery with enhanced condensational growth using an individual path model of the entire tracheobronchial airwaysTargeting aerosol deposition to and within the lung airways using excipient enhanced growthEvaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial modelIn vitro performance testing of the novel Medspray wet aerosol inhaler based on the principle of Rayleigh break-upNoninvasive routes of proteins and peptides drug delivery.Performance of combination drug and hygroscopic excipient submicrometer particles from a softmist inhaler in a characteristic model of the airways.Inhaled insulin delivery--where are we now?Aerodynamic factors responsible for the deaggregation of carrier-free drug powders to form micrometer and submicrometer aerosols.Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium.Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations.Single-use disposable dry powder inhalers for pulmonary drug delivery.Advances in pulmonary delivery of nanoparticles.Third-generation long-acting β₂-adrenoceptor agonists: medicinal chemistry strategies employed in the identification of once-daily inhaled β₂-adrenoceptor agonists.Inhalation therapy to treat pulmonary arterial hypertension.Loco-regional administration of nanomedicines for the treatment of lung cancer.Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases?Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways.Effects of the laryngeal jet on nano- and microparticle transport and deposition in an approximate model of the upper tracheobronchial airways.Effects of device and formulation on in vitro performance of dry powder inhalers.
P2860
Q28383212-213583EE-F78E-491F-88D5-D133372C293AQ28386376-1CD7CF7C-BB29-4869-B38A-CBC794467888Q28390979-40D26290-5C4C-49C7-96FA-84540BCE6E45Q28397573-90935F13-D292-4E0F-9EFD-3AF7A4B48BFBQ33309292-0E54F786-D721-48E9-BC92-3BB10F339803Q36029817-98A0EAFD-0EB9-49D3-9457-46225336CC6AQ36417205-4F9FF4C9-0D94-4C1C-A7C0-C75B464649B7Q36616573-D0EE162F-8CD4-49D6-AB17-6270772A011AQ36989479-EDB99013-A760-4585-A7C6-9D7BB43ABB2FQ37077219-4547ACDB-6CC8-4BF7-B364-3583B169BB8CQ37626575-E3FE8572-CA26-4BF3-83F0-A2FBDFFDEFA6Q37809879-FCAC3AA1-5D5C-43FD-837A-7E4C6036E12DQ37909465-F56E9D41-C217-49E6-B16E-A13F681CF18EQ37937552-28E57127-679D-414D-9588-7D3C504AC232Q38162947-58C0A833-110C-4585-828C-5FE8E1A127AEQ38639228-69AF2AE3-2DFD-4580-877C-C4AA634AAB77Q39031123-0BA87B21-3C03-4D33-8F67-E922474E8482Q39658347-B65CC6F6-7C25-4E80-8A8C-5C653B83AE1DQ40106626-4E4D8F92-6CBB-4424-BF0D-D81CDD460922Q42218975-3D2EAA2C-DB9E-4EAD-8420-7F1B542F37CD
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Drug delivery devices: issues in drug development.
@ast
Drug delivery devices: issues in drug development.
@en
type
label
Drug delivery devices: issues in drug development.
@ast
Drug delivery devices: issues in drug development.
@en
prefLabel
Drug delivery devices: issues in drug development.
@ast
Drug delivery devices: issues in drug development.
@en
P1476
Drug delivery devices: issues in drug development.
@en
P2093
Peter R Byron
P304
P356
10.1513/PATS.200403-023MS
P577
2004-01-01T00:00:00Z